148 related articles for article (PubMed ID: 32778513)
1. Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in Myelofibrosis.
Castillo-Tokumori F; Talati C; Al Ali N; Sallman D; Yun S; Sweet K; Padron E; Lancet J; Komrokji R; Kuykendall AT
Clin Lymphoma Myeloma Leuk; 2020 Dec; 20(12):e956-e960. PubMed ID: 32778513
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis.
Quintás-Cardama A; Kantarjian HM; Manshouri T; Thomas D; Cortes J; Ravandi F; Garcia-Manero G; Ferrajoli A; Bueso-Ramos C; Verstovsek S
J Clin Oncol; 2009 Oct; 27(28):4760-6. PubMed ID: 19720904
[TBL] [Abstract][Full Text] [Related]
3. [Transfusion independence achieved with pomalidomide therapy in a patient with primary myelofibrosis].
Edahiro Y; Gotoh A; Inano T; Tsutsui M; Tsukune Y; Yasuda H; Komatsu N
Rinsho Ketsueki; 2018; 59(3):323-325. PubMed ID: 29618692
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
[TBL] [Abstract][Full Text] [Related]
5. Improvement of the hematologic toxicities of ruxolitinib in patients with MPN-associated myelofibrosis using a combination of thalidomide, stanozolol and prednisone.
Duan M; Zhou D
Hematology; 2019 Dec; 24(1):516-520. PubMed ID: 31242816
[No Abstract] [Full Text] [Related]
6. Pomalidomide therapy for multiple myeloma and myelofibrosis: an update.
Lacy MQ; Tefferi A
Leuk Lymphoma; 2011 Apr; 52(4):560-6. PubMed ID: 21338284
[TBL] [Abstract][Full Text] [Related]
7. [Effectiveness and safety of lenalidomide in myelofibrosis patients: a case series from the Spanish compassionate use program].
Castillo I; Ojea MA; Boqué C; Asensio A; Hermosilla MM; Blanes M;
Farm Hosp; 2013; 37(2):135-42. PubMed ID: 23789757
[TBL] [Abstract][Full Text] [Related]
8. Thalidomide and lenalidomide in primary myelofibrosis.
Holle N; de Witte T; Mandigers C; Schaap N; Raymakers R
Neth J Med; 2010 Aug; 68(1):293-8. PubMed ID: 20739725
[TBL] [Abstract][Full Text] [Related]
9. Comparison of thalidomide and lenalidomide as therapy for myelofibrosis.
Jabbour E; Thomas D; Kantarjian H; Zhou L; Pierce S; Cortes J; Verstovsek S
Blood; 2011 Jul; 118(4):899-902. PubMed ID: 21622644
[TBL] [Abstract][Full Text] [Related]
10. Experience with lenalidomide in an Austrian non-study population with advanced myelofibrosis.
Burgstaller S; Fridrik M; Hojas S; Kühr T; Ludwig H; Mayrbäurl B; Pöhnl R; Pötscher M; Schlögl E; Zauner D; Thaler J; Gisslinger H
Wien Klin Wochenschr; 2013 Apr; 125(7-8):196-9. PubMed ID: 23536018
[TBL] [Abstract][Full Text] [Related]
11. Does anything work for anaemia in myelofibrosis?
Birgegård G
Best Pract Res Clin Haematol; 2014 Jun; 27(2):175-85. PubMed ID: 25189728
[TBL] [Abstract][Full Text] [Related]
12. Immunomodulatory agents in myelofibrosis.
Tabarroki A; Tiu RV
Expert Opin Investig Drugs; 2012 Aug; 21(8):1141-54. PubMed ID: 22668122
[TBL] [Abstract][Full Text] [Related]
13. [Research and Applications Progress of Lenalidomide for Myelofibrosis--Review].
Fan WJ; Wu T; Chen JW; Bai H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Dec; 26(6):1854-1857. PubMed ID: 30501733
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide therapy in myelofibrosis with myeloid metaplasia.
Tefferi A; Cortes J; Verstovsek S; Mesa RA; Thomas D; Lasho TL; Hogan WJ; Litzow MR; Allred JB; Jones D; Byrne C; Zeldis JB; Ketterling RP; McClure RF; Giles F; Kantarjian HM
Blood; 2006 Aug; 108(4):1158-64. PubMed ID: 16609064
[TBL] [Abstract][Full Text] [Related]
15. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.
Luo X; Xu Z; Li B; Qin T; Zhang P; Zhang H; Fang L; Pan L; Hu N; Qu S; Zhang Y; Huang G; Peter Gale R; Xiao Z
Blood Cancer J; 2018 Jan; 8(1):9. PubMed ID: 29335406
[TBL] [Abstract][Full Text] [Related]
16. Management of Myelofibrosis-Associated Anemia: Focus on Standard Agents and Novel Therapeutics in Phase 3 Clinical Trials.
Stein BL
Curr Hematol Malig Rep; 2021 Oct; 16(5):483-489. PubMed ID: 34499329
[TBL] [Abstract][Full Text] [Related]
17. Impact of last lenalidomide dose, duration, and IMiD-free interval in patients with myeloma treated with pomalidomide/dexamethasone.
Kastritis E; Roussou M; Gavriatopoulou M; Kanellias N; Migkou M; Eleutherakis-Papaiakovou E; Ziogas DC; Fotiou D; Ntanasis-Stathopoulos I; Dialoupi I; Giannouli S; Tsirigotis P; Delimpasi S; Mparmparousi D; Spyropoulou-Vlachou M; Xirokosta A; Terpos E; Dimopoulos MA
Blood Adv; 2019 Dec; 3(23):4095-4103. PubMed ID: 31821457
[TBL] [Abstract][Full Text] [Related]
18. The Treatment Landscape of Myelofibrosis Before and After Ruxolitinib Approval.
Kuykendall AT; Talati C; Al Ali N; Sweet K; Padron E; Sallman DA; Lancet JE; List AF; Zuckerman KS; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):e45-e53. PubMed ID: 28869184
[TBL] [Abstract][Full Text] [Related]
19. [Review of evidence of thalidomide and lenalidomide in different hematological diseases: chronic lymphocytic leukemia, primary amyloidosis, myelofibrosis and syndrome myelodysplastic].
Jiménez Lozano I; Juárez Jiménez JC
Farm Hosp; 2013; 37(4):322-34. PubMed ID: 24010694
[TBL] [Abstract][Full Text] [Related]
20. Long-term results of a phase II trial of lenalidomide plus prednisone therapy for patients with myelofibrosis.
Chihara D; Masarova L; Newberry KJ; Maeng H; Ravandi F; Garcia-Manero G; Ferrajoli A; Cortes J; Kantarjian H; Verstovsek S
Leuk Res; 2016 Sep; 48():1-5. PubMed ID: 27416326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]